Fundación Respirar - Consultorios Médicos Dr. Doreski
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sariego, Irmgadt Annelise Goecke
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Calabresse, Renato Eduardo Jimenez
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Akhvlediani, Rima
empacific, NCT06284954: A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Recruiting
2
42
Europe, US, RoW
Empasiprubart IV, ARGX-117, Placebo IV
argenx
Dermatomyositis, Myositis
07/25
01/28
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sariego, Irmgadt Annelise Goecke
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE

Recruiting
2
532
Europe, Japan, US, RoW
M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA
Systemic Lupus Erythematosus
04/25
04/25
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Calabresse, Renato Eduardo Jimenez
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26
Akhvlediani, Rima
empacific, NCT06284954: A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Recruiting
2
42
Europe, US, RoW
Empasiprubart IV, ARGX-117, Placebo IV
argenx
Dermatomyositis, Myositis
07/25
01/28
GALACELA, NCT05856448: A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus

Active, not recruiting
2
186
Europe, US, RoW
GLPG3667, Placebo
Galapagos NV
Systemic Lupus Erythematosus
10/25
03/26

Download Options